Subcutaneous administration of bortezomib significantly decreased the incidence and delayed the deve

来源 :The 35th World Congress of the International Society of Hema | 被引量 : 0次 | 上传用户：haidao_123456789

【摘要】

：

【作者】

：

Yan Xu Shuhui Deng Gang An Zengjun Li Weiwei Sui Wei Liu Lugui Qiu

【机构】

：

Institute of Hematology & Blood Diseases Hospital,Chinese Acadmic Medical Science & Peking Union Med

【出处】

：

The 35th World Congress of the International Society of Hema

【发表日期】

：

2014年5期

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

Background Intravenous injection is the standard administration route of bortezomib.However,peripheral neuropathy always limited the use of bortezomib.Subcutaneous administration is an important alternative with comparable efficacy but better safety profile.However,no relative study have been done in China.

其他文献

Molecular Cytogenetic Aberrations in Thai Patients with Multiple Myeloma Ramathibodi Experience

Introduction Cytogenetic abnormality plays an important role in prognosis of patients with multiple myeloma (MM).Conventional cytogenetic assay reveals limited results.In this study,we performed inter

会议

Fluorescence in situ hybridization detection of cytogenetic abnormalities and prognosis in multiple

Background Multiple myeloma (MM) is a plasma-cell malignancy manifested accumulation of abnormal plasma cells in the bone marrow.The purpose of this study is to evaluate the prognosis in patients with

会议

Protein Turnover Assay (ProTA) A Novel Tool For Profiling Human Protein Degradome to Elucidate Cellu

Purpose Global change in protein turnover (protein degradome) constitutes a central part of cellular responses to intrinsic or extrinsic stimuli.However,profiling protein degradome remains technically

会议

Fenretinide effects myeloma side population mediating tha reactive oxygen species-dependent mechanis

Tumor initiating cells play important roles in multiple myeloma (MM) progression,relapse,recurrence,and are critical target for therapy.However,quite few agents have been shown to target tumor initiat

会议

Bortezomib-Based Versus Nonbortezomib-Based Post-Transplantation Treatment in Multiple Myeloma Patie

Objective The aim of this meta-analysis of data from phase Ⅲ studies is to characterize efficacy and safety of bortezomib-based versus nonbortezomib-based post-transplantation therapy in patients with

会议

Modified Bortezomib, Adriamycin and Dexamethasone (PAD) Regimen in Advanced Multiple Myeloma

The PAD regime,composed of bortezomib,adriamycin and dexamethasone,improves the outcomes of patients with advanced multiple myeloma (MM),but at the same time produces high frequency of serious toxic s

会议

Silencing cdc37 blocks proliferation but may confer drug resistance in multiple myeloma

Heat shock protein 90 (HSP90) is one of the most active molecular chaperones in cell,participating in cellular stress response as well as client protein maturation and stabilization.Cdc37 (cell divisi

会议

Novel agents induction therapy followed with or without autologous stem cell transplantation in youn

Objective To define the role of autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM) in the era of novel agents,we analyzed the follow-up data in patients treated with

会议

Management of Painful Spinal Lesions Caused by Multiple Myeloma Using Percutaneous Vertebroplasty

Background Multiple myeloma (MM) is a tumor of b cell origin.It is estimated that the bones are involved at presentation in 70 ％to 100 ％of patients.Spinal lesions with marked destruction are common si

会议

Human umbilical cord blood-derived stromal cells A new resource for the proliferation and apoptosis

Background/Objective Bone marrow stromal cells (BMSCs) can support multiple myeloma (MM) disease progression and resistance to chemotherapy.The proliferation of MM cells may be suppressed by modifying

会议

Subcutaneous administration of bortezomib significantly decreased the incidence and delayed the deve

与本文相关的学术论文